IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for smallpox infection.

Abstract

Bavarian Nordic is developing IMVAMUNE, which is based on a live attenuated modified vaccinia Ankara virus, for the potential prevention of smallpox infection, particularly in those patients contraindicated to traditional smallpox vaccines, such as the immunocompromised and those with eczema or dermatitis. In phase I and II clinical trials, IMVAMUNE was highly immunogenic and safe with no unexpected side effects or serious adverse effects reported in either healthy volunteers, those immunocompromised by HIV infection or in volunteers with atopic dermatitis. Additional phase II trials were ongoing in these groups at the time of publication and phase III trials were planned for 2009.

• Authors: Taff Jones
• Journal: Current opinion in molecular therapeutics (Curr Opin Mol Ther) Vol. 10 Issue 4 Pg. 407-17 (Aug 2008) ISSN: 1464-8431 [Print] England
• PMID: 18683106 (Publication Type: Historical Article, Journal Article)

Chemical References

• Smallpox Vaccine
• Vaccines, Attenuated

Topics

• Animals
• Clinical Trials as Topic
• Dermatitis, Atopic (immunology)
• HIV Infections (immunology)
• History, 18th Century
• History, 19th Century
• History, 20th Century
• History, Ancient
• Humans
• Smallpox (history, immunology, prevention & control)
• Smallpox Vaccine (history, immunology, therapeutic use)
• Vaccines, Attenuated (immunology, therapeutic use)
• Vaccinia virus (genetics, immunology)